Low back pain is the single most common driver of lost work time and one of the most contested diagnoses in the workers’ compensation system, and spinal fusion surgery — the procedure most often authorized as a last resort — remains among the most expensive, slowest-recovering, and most heavily litigated treatments claims professionals encounter. That landscape shifted in mid-December 2025, when the U.S. Food and Drug Administration granted full premarket approval to the DIAM Spinal Stabilization System, the first posterior, motion-preserving implant cleared in the United States as an alternative to fusion for chronic low back pain caused by degenerative disc disease.

The device, manufactured by Companion Spine, received FDA approval on the strength of a prospective, randomized, multicenter Investigational Device Exemption trial with an average follow-up of 11.5 years, according to the company’s December 15, 2025 announcement. Notably, the FDA granted the approval without requiring a post-approval confirmatory study, a step the agency reserves for applications it considers to be supported by unusually strong clinical evidence.

To understand why this approval matters, it helps to understand the treatment gap it is meant to fill. When a worker develops chronic low back pain from degenerative disc disease that does not resolve with physical therapy, medication, and injections, the traditional next step has long been spinal fusion — permanently joining two or more vertebrae together with screws, rods, and bone graft to eliminate motion at the painful segment. Fusion can be effective, but it is also invasive, requires a lengthy recovery, eliminates natural spinal motion at the treated level, places additional mechanical stress on adjacent vertebrae, and forecloses future treatment options if it fails. Many patients with moderate symptoms have historically been left in a gap: too impaired for continued conservative care, but not considered good candidates for the invasiveness of fusion.

The DIAM system is designed for that gap. It is an H-shaped spacer made of silicone and polyester that is implanted between the spinous processes — the bony protrusions at the back of each vertebra — at a single level from L2 to L5. Secured with polyester tethers and titanium crimps, the device is intended to offload stress from the painful disc and posterior joints while preserving natural motion at the treated segment, rather than eliminating it. The procedure is performed on an outpatient basis through a minimally invasive posterior approach, and because it does not fuse the spine, it is designed to be removable and to leave future surgical options, including fusion, open if needed. The implant itself is not new internationally: more than 250,000 units have been implanted in over 200,000 patients across 76 countries since 1997, but this approval marks its first full U.S. clearance after a 20-year regulatory path that included a 2016 FDA advisory panel rejection over insufficient trial data.

The pivotal trial measured a composite clinical success endpoint at 24 months — combining pain relief, functional improvement, and the absence of device-related reoperation — and found a 67.4 percent success rate for DIAM patients compared with 11.9 percent for patients who continued non-operative care, a difference the company describes as showing a Bayesian posterior probability of superiority exceeding 0.999. Secondary measures reported by Companion Spine included a 77 percent responder rate on the Oswestry Disability Index and an 83.2 percent back pain responder rate at 24 months, with durability holding up over the long term: among the long-term follow-up cohort tracked for an average of 11.5 years, 86.4 percent maintained both disability and pain responder status, and 87 percent of patients said they would choose the same treatment again more than a decade later.

On safety, the company reported a 1.6 percent rate of device-related serious adverse events, no reported device migrations or mechanical failures through 11.5 years of follow-up, and a 95.7 percent freedom-from-device-removal rate at the same interval. Notably, according to the trial investigators quoted in the FDA announcement, none of the study patients who received the DIAM implant required conversion to spinal fusion during the study’s long-term follow-up period. Independent verification of these figures beyond the company’s own release and the underlying FDA premarket approval documentation will accumulate as the device enters broader U.S. use and registry data develops, and claims professionals should treat single-manufacturer clinical trial results with the same scrutiny they would apply to any sponsor-funded study, while recognizing that the FDA’s decision to waive a post-approval confirmatory trial reflects the agency’s own confidence in the existing evidence base.

Because DIAM is indicated only for patients with single-level lumbar degenerative disc disease who remain symptomatic after at least six months of non-operative care, utilization reviewers will need to confirm that conservative treatment was genuinely exhausted before a request reaches this stage — the same threshold question that already governs fusion requests, but now with a second surgical option in the mix rather than a binary choice between continued conservative care and fusion.

DIAM enters the U.S. market at a moment when spine surgeons and payers alike have been rethinking the “fusion-first” default for degenerative disc disease, a theme that was prominent at the 2026 annual meeting of the International Society for the Advancement of Spine Surgery, where motion-preserving technologies and their long-term economic sustainability were a central focus. Whether DIAM becomes a meaningful presence in workers’ compensation treatment plans will depend on real-world outcomes as more U.S. surgeons gain experience with the device, on how commercial and workers’ compensation payers approach coverage and fee-schedule classification for a device without an established coding history in this country, and on whether the favorable trial-population results hold up in the more medically and psychosocially complex population typical of workers’ compensation claims. Claims professionals reviewing lumbar spine treatment requests over the coming months should ask whether DIAM or a similar motion-preserving device was considered, and utilization review protocols may need updating as this option becomes more familiar to treating physicians and reviewers alike.